AVIR underwent a dramatic balance sheet contraction with total assets declining 32% while liabilities increased substantially, indicating potential financial distress or major corporate restructuring.
The company appears to have consumed significant resources, with stockholders' equity declining by $163.5 million despite maintaining higher cash levels, suggesting potential dilutive financing or major write-downs. The removal of core business description language about their HCV drug development program and Phase 3 trial timeline raises concerns about strategic direction changes or program delays.
AVIR's balance sheet reflects a concerning deterioration with total assets shrinking by $149.5 million while liabilities grew substantially from $25.8M to $39.8M. Despite cash increasing to $95.7M, the overall asset base contracted significantly and stockholders' equity fell by over one-third, indicating the company burned through substantial resources or took major write-downs. The financial picture suggests either aggressive spending on operations, dilutive capital raising, or asset impairments that materially weakened the balance sheet structure.
Liabilities grew 54.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash position surged 47.9% — strong cash generation or capital raise providing significant financial cushion.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 32.7% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 32.2% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →